The landmark study on Stockholm3 published in the leading urology journal European Urology has been selected as an Editor’s Choice article and highlighted on the home page of the journal’s website.

The study, published in October 2025, addresses a critical question in prostate cancer screening with Stockholm3: whether cancers detected at low PSA levels but with elevated Stockholm3 scores are clinically meaningful. This long-term follow-up from the population-based STHLM3 study shows that they are. Men diagnosed with prostate cancer at PSA levels below 3 ng/mL but with elevated Stockholm3 scores were approximately nine times more likely to experience high-risk biochemical recurrence after curative treatment compared to men who had higher PSA levels but low Stockholm3 risk (HR 8.8; 95% CI: 1.06–72).[1]

These findings demonstrate that Stockholm3 identifies biologically aggressive cancers that are often missed by traditional PSA-based screening. Without Stockholm3, many of these cancers would remain undetected at earlier stages and may progress beyond the window of curability.

European Urology selects a limited number of Editor’s Choice articles that the editors consider to be of particular importance in the field.

“This recognition from European Urology underscores the strength of the clinical evidence behind Stockholm3 and the importance of more precise prostate cancer screening strategies,” says Martin Steinberg, CEO of A3P Biomedical. “We are encouraged to see the study receiving this level of editorial attention from the leading journal in the field.”

[1] Vigneswaran, Hari T et al. “Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.” European urology vol. 89,1 (2026): 82-90. doi:10.1016/j.eururo.2025.10.001

For additional information, please contact:

Cecilia Edström, acting CFO
Telephone: +46 72 226 23 28
Email: cecilia.edstrom@a3p.com

About A3P Biomedical

A3P Biomedical is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P Biomedical is headquartered in Stockholm, Sweden. For more information, please visit www.a3p.com

About Stockholm3

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care. For more information about Stockholm3 and our clinical studies please visit www.stockholm3.com/

About prostate cancer

Prostate cancer is the most common cancer in men. In 2020, the global incidence of new prostate cancer cases was 1.4 million, and prostate cancer specific mortality 370,000. Global prostate cancer incidence and mortality is expected to rise by 100% and 85% respectively by 2040, driven by an ageing population.

Attachments

Landmark Stockholm3 study highlighted as Editor’s Choice in European Urology

Läs mer på MFN